Stock Research: Castle Biosciences

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Castle Biosciences

NasdaqGM:CSTL US14843C1053
40
  • Value
    98
  • Growth
    1
  • Safety
    Safety
    24
  • Combined
    14
  • Sentiment
    61
  • 360° View
    360° View
    40
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Castle Biosciences, Inc. is a diagnostics company improving health through tests that guide patient care. The company operates in the healthcare industry, focusing on diagnostic tests for skin cancers, Barrett’s esophagus, mental health conditions, and uveal melanoma, with products including DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. No specific regions of operation are mentioned. In the last fiscal year, the company had a market cap of $549 million, profits of $272 million, revenue of $332 million, and 761 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 40 (better than 40% compared with alternatives), overall professional sentiment and financial characteristics for the stock Castle Biosciences are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Castle Biosciences. The consolidated Sentiment Rank has a good rank of 61, which means that professional investors are more optimistic about the stock than for 61% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 98 or better than 98% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 24, meaning that the share price of Castle Biosciences is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 1. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
24 7 35 26
Growth
1 24 11 55
Safety
Safety
98 79 73 84
Sentiment
61 65 69 47
360° View
360° View
40 25 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
97 97 93 97
Opinions Change
50 70 50 26
Pro Holdings
n/a 19 39 3
Market Pulse
64 40 47 72
Sentiment
61 65 69 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
24 7 35 26
Growth
1 24 11 55
Safety Safety
98 79 73 84
Combined
14 13 16 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
28 4 78 24
Price vs. Earnings (P/E)
15 7 12 3
Price vs. Book (P/B)
55 59 80 59
Dividend Yield
1 1 1 1
Value
24 7 35 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
1 4 27 74
Profit Growth
4 92 32 6
Capital Growth
4 6 18 95
Stock Returns
28 53 19 21
Growth
1 24 11 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
81 91 94 90
Refinancing
92 96 92 94
Liquidity
89 4 1 15
Safety Safety
98 79 73 84

Similar Stocks

Discover high‑ranked alternatives to Castle Biosciences and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.